经皮肝脏灌注对比最佳替代治疗转移性葡萄膜黑色素瘤的荟萃分析
该荟萃分析纳入11项研究(PHP组455例,BAC组125例),比较经皮肝脏灌注(PHP)与最佳替代治疗(BAC)在转移性葡萄膜黑色素瘤(mUM)中的疗效与安全性。PHP组客观缓解率(47.4% vs 6.0%)、1年无进展生存率(30.1% vs 6.4%)和中位无进展生存期(7.7 vs 2.6个月)均优于BAC,但总生存无明确获益。
要点
- PHP较BAC显著提高ORR(47.4% vs 6.0%)和PFS(mPFS 7.7 vs 2.6个月)。
- PHP与BAC的1年OS(65.5% vs 64.3%)和mOS(17.3 vs 14.0个月)无明确生存获益。
- PHP研究中最常见毒性为血液学不良事件。
核心结论
- PHP较BAC改善mUM患者的ORR和PFS,但未观察到明确的生存获益。
研究设计与样本
- 系统检索PubMed、Embase、Cochrane和Web of Science至2026年2月17日,纳入11项研究。
- PHP组455例来自9项研究,BAC组125例来自3项研究(其中1项同时报告两组)。
- 采用限制性最大似然估计的随机效应模型进行荟萃分析。
主要发现
- PHP组汇总1年OS为65.5%(95%CI 52.8-75.5%),BAC组为64.3%(95%CI 13.3-90.7%)。
- PHP组汇总2年OS为35.4%(95%CI 28.5-42.4%),BAC组为28.1%(95%CI 9.6-50.2%)。
- PHP组mOS为17.3个月(95%CI 11.8-22.8),BAC组为14.0个月(95%CI 4.3-23.6)。
- PHP组ORR为47.4%,BAC组为6.0%;PHP组1年PFS为30.1%,BAC组为6.4%。
- PHP组mPFS为7.7个月,BAC组为2.6个月;PHP研究中血液学不良事件最常见。
临床怎么用
- PHP可作为mUM的肝脏定向治疗选择,在ORR和PFS方面优于BAC。
- 因无明确OS获益,选择PHP时需综合评估患者获益与血液学毒性风险。
局限性
- BAC队列来源于随机试验的衍生队列,样本量较小(125例)且置信区间宽。
- 纳入研究多为单臂设计,缺乏直接头对头比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Evidence on the efficacy of percutaneous hepatic perfusion (PHP) in metastatic uveal melanoma (mUM) is largely derived from single-arm studies without comparators, complicating interpretation of treatment benefit, particularly for survival. This meta-analysis aimed to synthesize available evidence on the efficacy and safety of PHP in patients with mUM and compare outcomes with best alternative care (BAC). MATERIAL AND METHODS: PubMed, Embase, Cochrane, and Web of Science were searched from database inception to Feb 17, 2026. Studies evaluating PHP in patients with mUM and BAC cohorts derived from randomized trials of PHP or isolated hepatic perfusion were included. The endpoints were 1-year overall survival (OS), 2-year OS, median OS (mOS), 1-year progression-free survival (PFS), median PFS (mPFS), overall response rate (ORR), and safety. Random-effects meta-analyses were performed using restricted maximum likelihood estimation. RESULTS: Eleven studies were included (one reporting on both PHP and BAC), comprising 455 patients treated with PHP (nine studies) and 125 treated with BAC (three studies). The pooled 1-year OS was 65.5% (95% CI 52.8-75.5%) for PHP and 64.3% (95% CI 13.3-90.7%) for BAC. The pooled 2-year OS was 35.4% (95% CI 28.5-42.4%) and 28.1% (95% CI 9.6-50.2%), and mOS 17.3 months (95% CI 11.8-22.8) and 14.0 months (95% CI 4.3-23.6), respectively. PHP was associated with higher ORR (47.4% vs 6.0%), longer 1-year PFS (30.1% vs 6.4%) and mPFS (7.7 vs 2.6 months). Hematologic adverse events were the most frequently reported toxicities in PHP studies. CONCLUSION: PHP is associated with improved ORR and PFS compared with BAC in patients with mUM, although no clear survival benefit was observed.
引用
- van den Hoek L, Dekkers O, Burgmans M, et al. Percutaneous hepatic perfusion versus best alternative care as treatment for metastatic uveal melanoma: A meta-analysis. Eur J Cancer. 2026. PMID: 42330566. doi:10.1016/j.ejca.2026.116893
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。